Table 2.
Clinical profile at baseline
| Cannabis use Reduction Group N=152 |
Cannabis Increase Group N=150 |
Total N=302 |
|
|---|---|---|---|
| Cannabis use in past 30 days (mean/SD) | 27.2/4.8 | 24.8/7.2 | 26.0/6.2 |
| Number of standard alcohol drinks per week (mean/SD) | 4.0/7.2 | 4.9/6.8 | 4.5/7.0 |
| Number of Cigarettes per week (mean/SD) | 22.4/41.3 | 21.1/43.8 | 21.8/42.5 |
| N-acetylcysteine/Placebo (%) | 45.4/54.6 | 56.0/44.0 | 50.7/49.3 |
| Anxiety (Mean/SD) | 6.3/3.8 | 6.5/4.0 | 6.4/3.9 |
| Above the normal range (N/%) | 57/37.5 | 51/34.0 | 108/35.8 |
| Depression (Mean/SD) | 3.9/3.2 | 4.0/3.4 | 4.0/3.3 |
| Above the normal range (N/%) | 31/13.8 | 26/17.4 | 47/15.5 |
| Quality of Life (Mean/SD) | 7.4/10.8 | 8.5/11.0 | 8.0/10.9 |
| >=14 days (N/%) | 28/18.4 | 36/24.0 | 64/21.2 |
| Sleep Quality (Mean/SD) | 6.5/3.3 | 6.3/3.3 | 6.4/3.3 |
| Poor sleep quality (N/%) | 105/69.1 | 103/68.7 | 208/68.9 |
There were no significant differences between two groups for any characteristic except for cannabis use in 30 days prior to informed consent. (p<0.01 by chi-square test and T-test)